KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Shares Issued (2018 - 2025)

Historic Shares Issued for Vir Biotechnology (VIR) over the last 8 years, with Q2 2025 value amounting to $1.2 million.

  • Vir Biotechnology's Shares Issued fell 5132.3% to $1.2 million in Q2 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 1638.97%. This contributed to the annual value of $3.8 million for FY2024, which is 1214.1% down from last year.
  • According to the latest figures from Q2 2025, Vir Biotechnology's Shares Issued is $1.2 million, which was down 5132.3% from $598000.0 recorded in Q1 2025.
  • In the past 5 years, Vir Biotechnology's Shares Issued ranged from a high of $3.7 million in Q3 2021 and a low of $221000.0 during Q1 2024
  • Over the past 5 years, Vir Biotechnology's median Shares Issued value was $1.2 million (recorded in 2024), while the average stood at $1.6 million.
  • The largest annual percentage gain for Vir Biotechnology's Shares Issued in the last 5 years was 154475.52% (2021), contrasted with its biggest fall of 9884.98% (2021).
  • Vir Biotechnology's Shares Issued (Quarter) stood at $3.4 million in 2021, then tumbled by 72.92% to $932000.0 in 2022, then fell by 4.72% to $888000.0 in 2023, then soared by 30.74% to $1.2 million in 2024, then decreased by 0.17% to $1.2 million in 2025.
  • Its Shares Issued stands at $1.2 million for Q2 2025, versus $598000.0 for Q1 2025 and $1.2 million for Q4 2024.